Background: Hepatitis is the inflammation of liver and there are many reasons of hepatitis. Among these reasons the viral hepatitis due to hepatitis B virus (HBV) and hepatitis C Virus (HCV) are the common hepatic infections and the major causes of liver cancer and liver cirrhosis in the world especially in Asia and Medal east. HBV and HCV infections are having very high mortality ratio in Europe and every year millions of people become infected and die due to HBV or HCV in Europe and Worldwide. That’s why viral hepatitis needs a serious consideration and perfect treatment.

Objective: Objective of the study was to analyze the role of ribavirin in HCV treatment and to observe the virological response and relapse against it by using statistical meta-analytical techniques.

Selection criteria and data collection: For this meta-analysis I used the publication databases PubMed, ScienceDirect and Google Scholar to collect all research articles describing treatment and response of HCV and using the antiviral drugs Ledipasvir and Sofosbuvir (control group) in combination with the active agent Ribavirin.

Method and Methodology: Meta-analysis was performed using the statistical package R and the package metafore.

Result and conclusion: The result shows that the use of ribavirin with control group (ledipasvir and sofosbuvir) did not show a significant impact on the sustained virological response (SVR) during and after treatment. But addition of ribavirin in control group effectively reduced the rate of relapse after treatment.